Belrestotug is an Fc active human immunoglobulin G1, or IgG1, monoclonal antibody (mAb) targeting T cell immunoglobulin and immunoreceptor tyrosine-based inhibitory motif domains (TIGIT), an ...

GALAXIES Lung-201 trial showed ORR benefit but failed to meet PFS criteria for belrestotug combo vs. monotherapy. iTeos holds $624.3 million in cash as of March 31, 2025, with a projected runway ...

iTeos Therapeutics' belrestotug shows promising response rates in lung cancer trials, especially when combined with dostarlimab, despite significant safety concerns. Financially, ITOS has over 3 ...

ITOS iTeos Therapeutics Inc. - Clinically meaningful objective response rate (ORR) of 63.3-76.7% observed with belrestotug + dostarlimab combinations, with confirmed ORR (cORR) at ~60% for every dose ...

In May 2024, iTeos announced an interim assessment of the Phase 2 GALAXIES Lung-201 study of the belrestotug + dostarlimab doublet in previously untreated, locally advanced, or metastatic PD-L1 ...

About Belrestotug (EOS-448/GSK4428859A) Belrestotug is an Fc active human immunoglobulin G1, or IgG1, monoclonal antibody (mAb) targeting T cell immunoglobulin and immunoreceptor tyrosine-based ...

iTeos' Belrestotug shows efficacy in trials, backed by a strong cash runway. Learn why ITOS stock might thrive with strategic GSK collaboration.

Belrestotug is an Fc active human immunoglobulin G1, or IgG1, monoclonal antibody (mAb) targeting T cell immunoglobulin and immunoreceptor tyrosine-based inhibitory motif domains (TIGIT), an ...

– Belrestotug, formerly EOS-448, is advancing through multiple late-stage clinical trials including both doublet and triplet regimens – First-in-class program targeting a new mechanism of ...

In a securities filing, iTeos said it expects to incur $21.8 million to $24.7 million in severance and other termination-related costs, as well as $11.1 million in costs to wind down its clinical ...

GSK said it is ending the development program for the small-molecule drug Belrestotug. The British pharmaceutical giant said Tuesday that the decision is based on a new interim analyses from phase ...